http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9310761-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d5d8a3b3b3faac2562bcdcd68af92186 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7bc03cd73f75dc60f41b161291580d16 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G03C2001-0471 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2063 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5169 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51 |
| filingDate | 1992-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_065100345e1a4e846cd86c314dcde02c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69aaa5d5e2b92207c34d2f8abf393d25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64929f902a8f2596935367916a3f0ca6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32787577ea09e6004b2c14dc0264e81d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_359652fc8283f537413dfe1953359289 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57df750a836e204fc6bfa6364e7f76c3 |
| publicationDate | 1993-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-9310761-A1 |
| titleOfInvention | Medicament containing a 2-arylpropionic acid derivate as a nanosol and its preparation |
| abstract | Immediate-effect medicaments containing a pharmacologically active 2-arylpropionic acid derivate as a pharmaceutically applicable nanosol have a considerably improved action start and bioavailability of the active substance. The 2-arylpropionic acid derivates, for example ibuprofen, flurbiprofen and ketoprofen, that are scarcely soluble in an aqueous medium, are present in a gelatine-stabilised nanosol in a form that allows these active substances to be quickly and completely resorbed already in the stomach. The disclosed colloidal disperse system composed of a 2-arylpropionic acid derivate is prepared by selecting a gelatine or gelatine derivate according to their isoelectric point (IEP), so that their IEP is adapted to the charge of the 2-arylpropionic acid derivate particles, leading to a neutral charge when the gelatine or its derivate is combined with the undissolved 2-arylpropionic acid derivate at a determined pH value. The gelatine or its derivate are converted into an aqueous sol form, their pH value is set according to the IEP of the gelatine at a value that stabilises the nanoparticles of 2-arylpropionic acid derivate at an approximately or totally neutral charge. Before or after said last step, the 2-arylpropionic acid derivate is dissolved in the aqueous gelatine sol or a solution of 2-arylpriopionic acid derivate is blended with the aqueous gelatine sol. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013017333-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9611405-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0782851-A1 |
| priorityDate | 1991-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 63.